SK Life Science is a U.S. subsidiary of SK Biopharmaceuticals, headquartered in Paramus, New Jersey. The company's research and development focus centers on central nervous system (CNS) disorders and oncology, with a particular emphasis on precision-guided approaches and radiopharmaceutical therapy.
The firm currently has eight compounds under clinical development targeting both CNS disorders and cancer treatment. Its work in these therapeutic areas involves a collaborative team of researchers, scientists, and other professionals dedicated to accelerating development timelines.
SK Life Science operates within the broader SK Biopharmaceuticals group, which has received recognition from TIME as one of the World's Best Companies in 2024 and one of the 100 Most Influential Companies in 2023.
